Tag Archives: Risk

CareMetx, LLC’s OutcomeRx Launches a Reinsurance Product for Cell and Gene Therapies

OutcomeRx focuses on engaging with biotech companies to think through, structure, and manage value-based agreements

Thoughts Around COVID-19: Linking Business & Healthcare

HR leaders need to coordinate on their P&Ps, best practices while collaborating with other executives around managing all risks. Vendors and healthcare supply chains serving the workplace need more collaboration as part of managing all risks related to this pandemic event.

Closing Gaps in Health Plan Performance with Stakeholder Collaboration

Closing Gaps in Health Plan Performance with Stakeholder Collaboration Published in American Health & Drug Benefits, October 2015, Vol 8, No 7, Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment F. Randy Vogenberg, PhD, RPh, Partner, Access Market Intelligence Employers/Health Plans: For most commercial health plans and employer-sponsored health plans, immunology represents a […]

Employers Medical Stop Loss for Specialty Rxs

Employers Medical Stop Loss for Specialty Rxs – Employers will continue to experience escalating specialty Rx costs.  Effective but expensive non-substitutable products emerging from pharmaceutical manufacturers’ development pipelines will quickly and sharply drive both pharmacy and medical benefit year-over-year spending increases. Traditional risk management tools, like stop loss insurance policies are designed to mitigate risk […]

A Call to Action to Address Burden of Unintended Pregnancies in Plans’ Benefit Design

Benefit Design – A Call to Action to Address Burden of Unintended Pregnancies in Plans’ Benefit Design F. Randy Vogenberg, PhD, RPh Partner, Access Market Intelligence, Greenville, SC Adjunct Professor of Pharmacy Administration, Presbyterian College School of Pharmacy, Clinton, SC Adjunct Instructor, Outcomes and Health Policy, University of Illinois at Chicago College of Pharmacy Originally […]

Pharmaceutical Growth Driven by M&A and Shareholder Value

Pharmaceutical Growth Driven by M&A and Shareholder Value – Biologic and Pharmaceutical companies, along with their financial advisors or venture capital partners, have used mergers and acquisitions over the years to create value in order to keep their leading positions in a changing market. The era of pharmaceutical companies relying on blockbusters for their growth […]